01 / STRATEGY
Antigen & RNA Design
Antigen and neoantigen strategy, construct review, RNA architecture and expression-oriented study design.
PRECISION RNA · TRANSLATIONAL SCIENCE
From RNA design to scientific decision.
Research-stage platform development for oncology vaccines, metabolic therapeutics and non-viral RNA delivery. We connect molecular design, analytical insight and biological function to help programs move forward with confidence.
Independent research development · Partner-enabled execution
RNA ARCHITECTURE
DELIVERY → EXPRESSION → INSIGHT
Research expertise spanning
↗ Oncology vaccines↗ Metabolic therapeutics↗ LNP / LPX delivery↗ Translational immunology
Our expertise
Expertise that connects
molecules to medicine.
Tailored scientific development services spanning RNA design, delivery, analytics, biological function and technology transfer. Each project is scoped to its stage and evidence needs.
Discuss this service ↗
02 / DELIVERY
Non-Viral Delivery
LNP and lipoplex (LPX) formulation strategy, physicochemical characterization and delivery-performance comparisons.
03 / ANALYTICS
RNA Analytics & Quality
RNA identity and integrity, capping-related attributes, impurities, particle measurements and stability strategy.
04 / BIOLOGY
Potency & Immunology
Cell-based expression, functional potency and translational immune-response assessment for research programs.
05 / TRANSFER
CMC & Technology Transfer
Quality target product profiles, critical quality attributes, analytical gap assessments and technical transfer packages.
06 / ADVISORY
Program Leadership
Research strategy, specialized CRO coordination, program review and scientific decision support.
Research programs
Focused on complex
therapeutic challenges.
An integrated scientific framework, tailored to the disease biology and development decisions that matter.
Advance cancer vaccine ideas with stronger evidence.
Research-stage support linking antigen and RNA construct strategy to delivery, expression, immune profiling and preclinical decisions.
- Antigen and neoantigen evaluation
- RNA construct and expression analysis
- Innate and adaptive immune-response studies
- Preclinical and CMC development readiness
Metabolic research distinguishes RNA-encoded medicines from investigational active-vaccination concepts. All programs are research-stage; no clinical efficacy is implied.
Oncology immunogenomics · Research workflow
Personalized cancer vaccine design.
Connect tumor genomic evidence, HLA context, computational neoantigen prioritization, and mRNA construct research. NEXUS provides a framework for exploring evidence and accessing established public resources—not an automated clinical vaccine-design service.
- 01 / GENOMICS
Interpret tumor variation
Review tumor-versus-normal somatic variants, relevant fusions, and expression evidence.
- 02 / IMMUNOGENETICS
Consider HLA context
Use appropriately obtained individual HLA class I and II types for peptide presentation analyses.
- 03 / NEOANTIGENS
Prioritize candidates
Review predicted presentation, mutation support, expression, clonality, and normal-tissue relevance.
- 04 / RNA RESEARCH
Explore construct concepts
Assess antigen representation, RNA design hypotheses, delivery, and quality attributes.
- 05 / VALIDATION
Evaluate experimental evidence
Plan confirmation of peptide presentation, immunogenicity, specificity, and functional responses.
Cancer genomics
Explore public cancer datasets
Use population-level studies to generate hypotheses and identify relevant cancer-genomics evidence.
NIH · NCI / TCGAGenomic Data CommonsAccess open TCGA and other harmonized studies, mutations, expression, and cohort analyses. Some files require authorized access.Explore GDC Portal
Cancer cohort explorationcBioPortalExplore genomic alterations, gene-level profiles, and published tumor cohort studies.Explore cBioPortal
Variant annotationEnsembl VEPAnnotate and interpret variant consequences before downstream immunogenomics analysis.Open VEP
Neoantigen identification and prediction
Use established research tools
These independent services link to their maintainers. Tool access, licenses, inputs, and methods vary.
Variant-to-neoantigen pipelinepVACtools · pVACseqIdentify, filter, and prioritize candidate neoantigens using tumor variant data, optional expression evidence, and HLA context.View pVACtools
CD8 T-cell epitopesIEDB · MHC Class IPredict peptide–MHC-I binding; predictions are not proof of surface presentation or immunogenicity.Open MHC-I Predictor
CD4 T-cell epitopesIEDB · MHC Class IIEvaluate peptide–MHC-II binding hypotheses for helper T-cell epitope research.Open MHC-II Predictor
Open-source softwareMHCflurryPredict MHC-I binding, antigen processing, and peptide presentation using available models.Explore MHCflurry
Research pipeline · external dependenciesNeoPredPipeExplore a VCF-based neoantigen workflow. Check version compatibility and third-party tool licenses.View research source
Code and reproducibilitypVACtools Source CodeReview original implementation, releases, license, citations, and reproducible pipeline documentation.View GitHub repository
Scientific and privacy boundaries: TCGA/GDC cohorts support research but do not replace an individual patient's matched tumor/normal sequencing, HLA typing, and quality-controlled clinical data. Predicted neoantigens are unvalidated candidates and do not establish vaccine safety or efficacy. NEXUS does not collect patient data through this section, run these external pipelines, or deliver a clinically approved personalized vaccine. Do not upload protected patient information to public web tools; follow each provider's privacy, data-access, and commercial-license terms.
Discuss a research collaboration Research and preclinical development only · Independent external tools · No endorsement or affiliation implied.
How we work
From hypothesis to
decision-ready evidence.
A clear, stage-appropriate process built around defined deliverables, reproducibility and the scientific question behind each project.
01 —
Define the question
Align research objectives, program stage, decision criteria and study boundaries.
02 —
Design the study
Map constructs, assays, controls, analytical attributes and partner requirements.
03 —
Generate the data
Coordinate research execution in-house or through qualified external laboratories.
04 —
Interpret the results
Connect molecular quality, delivery behavior and biological performance.
05 —
Plan the next step
Document recommendations, risks and readiness for further development or transfer.
About NEXUS
Deep science. Clear decisions. Collaborative execution.
NEXUS RNA BioSolutions is conceived as a research and development organization informed by experience across mRNA vaccine platform development, translational immuno-oncology, molecular engineering, regulated analytical workflows and global technology transfer.
We aim to help early-stage teams ask sharper scientific questions, design more informative studies, and navigate critical research-to-development transitions—without requiring them to build every capability internally.
Start a scientific conversation ↗What guides us
Built for scientific clarity.
Fit-for-purpose science
Each study is designed around a clear development question, relevant measurements and decision criteria.
Partner-enabled execution
Specialized synthesis, formulation and other capabilities can be sourced through independently qualified providers.
Responsible development
Research-stage scopes, honest regulatory boundaries, documentation and intellectual-property review are central to the work.
Programs 04–09 · Connected RNA research software
RNA strategy → LNP formulation
→ DOE → analytical QC → immune response.
The connected research workbenches and specialized LNP mixture–process DOE now share a project ID and save their analyses to a single Project Hub. Move from molecular design to delivery planning, RNA quality attributes, cell-expression and antigen assays, and immune readouts—without claiming automatic GMP release or clinical performance.
04 / Construct architecture
RNA Construct Strategy Studio
Compare miRNA, RNAa, cytoplasmic or membrane mRNA, self-amplifying RNA and CAR-expression designs; save a modality-specific research strategy.
Open Construct Studio ↗05 / Targeted delivery
Targeted LNP Studio
Analyze lipid component mass, nominal N:P, two-stream flow split and ligand bookkeeping with evidence flags.
Open LNP Studio ↗07 / Molecular QC and potency-relevant analytics
RNA & RNA–LNP Analytical QC Studio
RT-qPCR, ddPCR, LC–MS cap composition, poly(A), agarose gel, Bioanalyzer, in vitro translation, A549/HEK293, LNP encapsulation and Western blots.
Open QC Analytics ↗06 / Immune biology
Immune Assay Interpretation Studio
Group independent samples and inspect ELISA, ELISpot, flow and cytotoxicity readouts without pseudoreplication.
Open Immune Studio ↗08 / Experimental design
Design of Experiments Studio
Full and fractional factorial screening, Box–Behnken and central-composite designs, randomized run sheets and a linked specialist mixture–process DOE.
Open DOE Studio ↗09 / Instrument results and method qualification
Instrument Import & Assay Qualification
Import qPCR, ddPCR, LC–MS, Bioanalyzer and plate reader CSV/TSV exports; review instrument flags, replicate precision, file hashes and user-defined analytical criteria.
Open Instrument Import ↗08B / Constrained formulations
LNP Mixture–Process DOE
Four-lipid molar fractions sum to 100%. Build bounds-aware randomized mixture/process run sheets; fit descriptive mixture models and link measured QC responses.
Open Mixture–Process DOE ↗NEW: Browser-local linked evidence, user-supplied QC criteria, controlled-project JSON exports.Open Project Hub ↗
Free computational research tools
Bioinformatics tools.
One connected workspace.
Direct access to NEXUS SeqFold Studio, protein back-translation, codon optimization, molecular cloning, plasmid analysis, qPCR/ddPCR primer-probe design, primer screening and sequence validation.
Protein / RNA · 01
Protein → DNA
Back-translation & codon optimizationUpload FASTA protein sequences or paste amino acids; back-translate to DNA and explore host-oriented codon choices.
Launch toolDNA design · 02
Plasmid Library
Reference vector explorationSearch available reference plasmids, review sequence features, and use a chosen vector in downstream design simulations.
Launch toolMolecular design · 03
Molecular Cloning
In-silico assembly planningExplore insert and vector combinations, cloning orientation, overlap-based assembly, and predicted products.
Launch toolMolecular design · 04
Primer Design
PCR primer screeningScreen candidate PCR primers for length, melting temperature, GC composition, and potential mismatches.
Launch toolProtein / RNA · 05
DNA Codon Optimization
Host-aware design optionsExplore codon usage preferences for a supplied nucleotide or protein sequence and export research reports.
Launch toolSequence analysis · 06
SeqFold Studio
DNA / RNA analysisSequence composition, ORF prediction, translation, alignment, restriction sites, and educational RNA pairing.
Launch toolSequence analysis · 07
Sequence Workbench
Plasmid maps & chromatogramsAnnotated plasmids, GenBank inspection, restriction digest simulations, multiple alignments, and Sanger AB1 reviews.
Launch toolResearch workflows · 08
Precision Workflows
Design and sequence reviewExplore the additional research-stage precision workflow features and their limitations.
Launch toolResearch workflows · 09
Validation Workflows
Data QC and confirmationReview research data validation, analytical quality, and sequence-related workflows.
Launch toolSeqFold · PCR assay design · 18
qPCR / ddPCR Primer + Probe Designer
RNA/DNA quantification assay candidatesDesign qPCR, RT-qPCR and ddPCR primer pairs with hydrolysis probes, approximate Tm checks, local FASTA specificity screens and CSV/JSON export.
Launch qPCR / ddPCR designer ↗RNA engineering · 10
RNA Construct Strategy
Modality architecture and QC planningDesign research plans for miRNA, RNAa, mRNA, self-amplifying RNA and CAR protein expression.
Launch tool ↗RNA expression engineering · 18
Coding Sequence & 5′/3′ UTR Designer
Synonymous ORF comparison · Kozak context · UTR motifsGenerate and compare CDS candidates, evaluate user-supplied 5′/3′ UTR sequences, assemble research-stage mRNA hypotheses and export FASTA/JSON/CSV.
Launch UTR Design Workbench ↗RNA engineering · DBTL / Structure · 19
DBTL & Structure Intelligence
Construct versions · local RNA pairing · AlphaFold DB / PDB · experimental learningCreate tracked transcript variants, import RNA dot-bracket and AlphaFold PDB structures, record expression/QC evidence by sample ID and compare measured results in Project Hub. Browser-local, no AI inference.
Launch DBTL & Structure Studio ↗Delivery research · 11
Targeted LNP Studio
Composition and nominal N:PMolar fraction, molecular-mass, ligand-bookkeeping, FRR/TFR and QC feasibility calculations.
Launch tool ↗Assay research · 12
Immune Assay Analysis
CSV grouping, statistics and flagsELISA, ELISpot, flow, cytotoxicity and research data summaries with CSV exports.
Launch tool ↗RNA / LNP QC · 13
Analytical QC Studio
ddPCR · qPCR · LC–MS · Bioanalyzer · WesternMethod checklists, raw-readout reduction, expression and encapsulation analysis, user-defined QC criteria.
Launch QC studio ↗Project evidence · 14
Connected Project Hub
Construct → LNP → QC → ImmuneTrack analytical evidence under one project ID, summarize saved analyses and download linked JSON reports.
Launch Project Hub ↗Experimental design · 15
DOE Worksheet
Factorial, Box–Behnken & response surfaceGenerate randomized experiment sheets, record results, review regression coefficients and save designs to your NEXUS research project.
Launch DOE Studio ↗Instrument analysis · 17
Instrument Import & Qualification
ddPCR · qPCR · LC–MS · Bioanalyzer · plate readerRead native CSV/TSV instrument exports, flag assay results, check user-defined precision and recovery, and create linked research reports.
Launch instrument importer ↗Constrained formulation DOE · 16
LNP Mixture–Process Worksheet
100 mol% composition · process factors · QC linkageGenerate feasible four-component lipid blends, randomized experimental plans, CSV exports and regression summaries without treating constrained percentages as independent.
Launch mixture DOE ↗Browser-local research utilities · No NEXUS login required · Not validated for clinical diagnosis or patient-specific treatment decisions.
Open SeqFold home ↗
Let's connect
Have a program worth exploring?
Whether you're evaluating an oncology RNA candidate, studying metabolic therapeutic concepts, or preparing for your next CMC milestone, we'd be glad to learn about your scientific challenge.
↗ Discovery and feasibility conversations
↗ Research-stage projects and collaborations
↗ Flexible scopes with qualified technical partners